tbuckley/cabot-search huggingface dataset:
Role of radiotherapy in patients with early-stage diffuse large B cell lymphoma who had achieved complete remission after chemotherapy.
Authors: Yuan Zhu, Jianjiang Liu, Na Zhang, Luying Liu, Ke Lu, Jialin Luo, Peng Liu, Ning Zhou
Journal: Journal of Clinical Oncology (2015)

e19502 Background: In the rituximab era, results of randomized trials and relevant studies focused on the role of consolidation radiotherapy (RT) in stage I–II diffuse large B cell lymphoma (DLBCL) were very few. The objective of this study is to investigate the role of consolidation radiotherapy (RT) in patients with stage I–II diffuse large B cell lymphoma (DLBCL) who had achieved complete remission after chemotherapy. Methods: Between January 2005 and December 2012, data for 376 patients with early stage DLBCL in complete remission after receiving cyclophosphamide, doxorubicin/epirubicin, vincristine and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) for at least three cycles were analyzed retrospectively. The median age was 53 years. Patients were divided into four groups: the R-CHOP group (93 patients), the R-CHOP+RT group (78 patients), the CHOP group (107 patients) and the CHOP+RT group (98 patients). All patients used Involved –field radiotherapy and the total dosage ranged from 30 Gy to 56Gy. Results: During a median follow-up of 53 months (range 4–128 months), the 5-year actuarial rates for disease free survival (DFS) and overall survival (OS) across all 376 patients were 80.7% and 87.6%, respectively. The 5-year DFS and OS of the R-CHOP+RT group were better than the R-CHOP group (5-year DFS: 94.9% vs. 88.1%, P = 0.030; 5-year OS: 97.9% vs. 86.0%, P = 0.026). No significant DFS or OS benefits were observed between the CHOP+RT group and the CHOP group (5-year DFS: 74.2% vs. 71.4%, P = 0.623; 5-year OS: 74.2% vs. 71.4%, P = 0.623). Conclusions: Our study indicates that consolidation radiotherapy can only improve DFS or OS of the patients with early stage DLBCL in complete remission after R-CHOP chemotherapy not CHOP regimen. All early stage patients are recommended to undergo rituximab-containing chemotherapy followed by consolidation radiotherapy. Relevant randomized trials are needed to testify this question.
Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogues is highly effective and reduces cost for hepatitis B prophylaxis after liver transplantation
Authors: R. Bielen, G. Robaeys, S. Schelfhout, D. Monbaliu, S. Van der Merwe, J. Pirenne, F. Nevens
Journal: Journal of Hepatology (2017)
Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid
Authors: Syed Beenish Rufai, Amit Singh, Jitendra Singh, Parveen Kumar, Manimuthu Mani Sankar, Sarman Singh, Kumari Nigam, Divya Sharma, Anil Kumar Gupta, Vivek Singh Rawat
Journal: Journal of Infection (2017)
Mortality from different causes associated with meat, heme iron, nitrates, and nitrites in the NIH-AARP Diet and Health Study: population based cohort study
Authors: Arash Etemadi, Rashmi Sinha, Mary H Ward, Barry I Graubard, Maki Inoue-Choi, Sanford M Dawsey, Christian C Abnet
Journal: BMJ (2017)

Objective To determine the association of different types of meat intake and meat associated compounds with overall and cause specific mortality.Design Population based cohort study.Setting Baseline dietary data of the NIH-AARP Diet and Health Study (prospective cohort of the general population from six states and two metropolitan areas in the US) and 16 year follow-up data until 31 December 2011.Participants 536 969 AARP members aged 50-71 at baseline.Exposures Intake of total meat, processed and unprocessed red meat (beef, lamb, and pork) and white meat (poultry and fish), heme iron, and nitrate/nitrite from processed meat based on dietary questionnaire. Adjusted Cox proportional hazards regression models were used with the lowest fifth of calorie adjusted intakes as reference categories.Main outcome measure Mortality from any cause during follow-up.Results An increased risk of all cause mortality (hazard ratio for highest versus lowest fifth 1.26, 95% confidence interval 1.23 to 1.29) and death due to nine different causes associated with red meat intake was observed. Both processed and unprocessed red meat intakes were associated with all cause and cause specific mortality. Heme iron and processed meat nitrate/nitrite were independently associated with increased risk of all cause and cause specific mortality. Mediation models estimated that the increased mortality associated with processed red meat was influenced by nitrate intake (37.0-72.0%) and to a lesser degree by heme iron (20.9-24.1%). When the total meat intake was constant, the highest fifth of white meat intake was associated with a 25% reduction in risk of all cause mortality compared with the lowest intake level. Almost all causes of death showed an inverse association with white meat intake.Conclusions The results show increased risks of all cause mortality and death due to nine different causes associated with both processed and unprocessed red meat, accounted for, in part, by heme iron and nitrate/nitrite from processed meat. They also show reduced risks associated with substituting white meat, particularly unprocessed white meat.
Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome
Authors: J R Schwartz, S Wang, J Ma, T Lamprecht, M Walsh, G Song, S C Raimondi, G Wu, M F Walsh, R B McGee, C Kesserwan, K E Nichols, B E Cauff, R C Ribeiro, M Wlodarski, J M Klco
Journal: Leukemia (2017)
Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults
Authors: A. M. Garber, W. S. Browner, E. L. Mazzaferri, J. R. Feussner, G. R. Kerby, G. C. Friesinger, K. I. Marton, A. I. Mushlin, V. A. Palda, G. E. Thibault, H. Sox, J. Barker, I. Hart, L. Blonde, L. Carravallah, J. Noble, F. D. Duffy, A. Feinberg, E. Wallace
Journal: Annals of Internal Medicine (1996)
Rook's Textbook of Dermatology, 9th edn. ChristopherGriffiths, JonathanBarker, TanyaBleiker, RobertChalmers, DanielCreamer, eds. Wiley-Blackwell, 2016; 4696 pp. ISBN: 978-1118441190. Price $860.
Authors: K.A. Ashack
Journal: British Journal of Dermatology (2017)
High-dose therapy in high-grade non-Hodgkins lymphoma patients: Comparison between unmanipulated peripheral blood progenitor cells and purged autologous bone marrow as stem cell support
Authors: Anne Kirsti Blystad, Stein Kvaloy, Jan Delabie, Emina Torlakovic, Harald Holte, Helen Vâlerhaugen, Erling Jakobsen, Gunnar Kvalheim
Journal: Blood (2000)
Are DAAs reducing barriers for HIV co-infected and people who inject drugs? A population based cohort study
Authors: N. Janjua, N. Islam, J. Wong, E.M. Yoshida, A. Ramji, H. Samji, Z.A. Butt, M. Chong, D. Cook, M. Alvarez, M. Tyndall, M. Krajden
Journal: Journal of Hepatology (2017)
Plasma expansion is key for sustained liver function and viability during normothermic and subnormothermic ex vivo machine perfusion in a rat model
Authors: J.M.G. Gassner, M. Nösser, R. Horner, K.H. Hillebrandt, S. Moosburner, L. Wegener, P. Demko, R. Arsenic, B. Strücker, J. Pratschke, I.M. Sauer, N. Raschzok
Journal: Journal of Hepatology (2017)
Potent Thrombolytic Effect of <i>N</i> -Acetylcysteine on Arterial Thrombi
Authors: Sara Martinez de Lizarrondo, Clément Gakuba, Bradley A. Herbig, Yohann Repessé, Carine Ali, Cécile V. Denis, Peter J. Lenting, Emmanuel Touzé, Scott L. Diamond, Denis Vivien, Maxime Gauberti
Journal: Circulation (2017)

Platelet cross-linking during arterial thrombosis involves von Willebrand Factor (VWF) multimers. Therefore, proteolysis of VWF appears promising to disaggregate platelet-rich thrombi and restore vessel patency in acute thrombotic disorders such as ischemic stroke, acute coronary syndrome, or acute limb ischemia. N-Acetylcysteine (NAC, a clinically approved mucolytic drug) can reduce intrachain disulfide bonds in large polymeric proteins. In the present study, we postulated that NAC might cleave the VWF multimers inside occlusive thrombi, thereby leading to their dissolution and arterial recanalization.Experimental models of thrombotic stroke induced by either intra-arterial thrombin injection or ferric chloride application followed by measurement of cerebral blood flow using a combination of laser Doppler flowmetry and MRI were performed to uncover the effects of NAC on arterial thrombi. To investigate the effect of NAC on larger vessels, we also performed ferric chloride-induced carotid artery thrombosis. In vitro experiments were performed to study the molecular bases of NAC thrombolytic effect, including platelet aggregometry, platelet-rich thrombi lysis assays, thromboelastography (ROTEM), and high-shear VWF string formation using microfluidic devices. We also investigated the putative prohemorrhagic effect of NAC in a mouse model of intracranial hemorrhage induced by in situ collagenase type VII injection.We demonstrated that intravenous NAC administration promotes lysis of arterial thrombi that are resistant to conventional approaches such as recombinant tissue-type plasminogen activator, direct thrombin inhibitors, and antiplatelet treatments. Through in vitro and in vivo experiments, we provide evidence that the molecular target underlying the thrombolytic effects of NAC is principally the VWF that cross-link platelets in arterial thrombi. Coadministration of NAC and a nonpeptidic GpIIb/IIIa inhibitor further improved its thrombolytic efficacy, essentially by accelerating thrombus dissolution and preventing rethrombosis. Thus, in a new large-vessel thromboembolic stroke model in mice, this cotreatment significantly improved ischemic lesion size and neurological outcome. It is important to note that NAC did not worsen hemorrhagic stroke outcome, suggesting that it exerts thrombolytic effects without significantly impairing normal hemostasis.We provide evidence that NAC is an effective and safe alternative to currently available antithrombotic agents to restore vessel patency after arterial occlusion.
Further Insights into the Hematological Disorders Observed in Shwachman-Diamond Syndrome: mTOR and STAT3 Hyper-Phosphorylation in CD4+ and CD8+ T Cells and Efficacy of Rapamycin Treatment
Authors: Valentino Bezzerri, Antonio Vella, Ilaria Meneghelli, Marco Cipolli, Claudio Sorio
Journal: Blood (2016)
Selective decontamination of the digestive tract halves the prevalence of ventilator-associated pneumonia compared to selective oral decontamination
Authors: Lieuwe D. Bos, Cheryl Stips, Laura R. Schouten, Lonneke A. van Vught, Maryse A. Wiewel, Luuk Wieske, Roosmarijn T. van Hooijdonk, Marleen Straat, Friso M. de Beer, Gerie J. Glas, Caroline E. Visser, Evert de Jonge, Nicole P. Juffermans, Janneke Horn, Marcus J. Schultz
Journal: Intensive Care Medicine (2017)
Elastogram quality assessment score in Vibration controlled transient elastography: diagnostic performance compared to digital morphometric analysis of liver biopsy
Authors: L.C. Mendes, N. Miotto, L.P. Zanaga, P.R.A. Ferreira, M.S.K. Lazarini, E.S.L. Gonçales, M.N. Pedro, F.L.G. Junior, R.S.B. Stucchi, A.G. Vigani
Journal: Journal of Hepatology (2017)
Epoetin biosimilars in the management of anemia secondary to chemotherapy in patients with solid tumors, lymphomas, and myelomas: The ORHEO study.
Authors: Elisabeth Luporsi-Gely, Pierre-Louis Soubeyran, Mauricette Michallet
Journal: Journal of Clinical Oncology (2013)

9564 Background: Chemotherapy may induce anemia with potentially severe consequences. The ORHEO (place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) study examined the efficacy and safety of epoetin alfa biosimilars (EABs) for the treatment of chemotherapy-induced anemia (CIA) in the clinical setting. Methods: ORHEO was a multicenter, observational, prospective, post-marketing study conducted in France. Patients with CIA (Hb &lt;110g/L) &gt;18 years old, with solid tumors, lymphomas or myelomas and eligible for epoetin alfa treatment were included in the study; they received EAB as prescribed by their physician. Baseline patient characteristics and anemia-related data including baseline and target Hb level epoetin treatment, adverse events and any other concomitant treatments prescribed were recorded. The primary endpoint was the rate of responders (defined as an increase in Hb levels to 100 g/L or at least 10 g/L since inclusion visit, or reaching target Hb set at start of study, without any blood transfusions in the 3 weeks prior to measurement) at +3 months (M3). Other endpoints included rate of responders at +6 months (M6) and safety endpoints. Results: 2310 patients (51.43 % male, 48.57 % female) from 232 centers were included in this study. At baseline 79.6% had solid tumors, 13.0% lymphomas and 7.4% myelomas. Median age was 68 y (range: 18–93). Mean baseline Hb level was 96 g/L with a target Hb level of &gt;= 120 g/L for 52.7% of patients. Almost all (99.9%) received the biosimilar epoetin zeta (median dose 30,000 IU/week) with 26.6% receiving additional iron supplementation. A total of 2056 and 1664 patients had at least one Hb level value at M3 and M6 respectively. The rate of response was 81.6% and 86.5% at M3 and M6, respectively. In total, 17.0% of treated patients reported clinically relevant adverse events (all grades), the most common being infections (5.0%) and thromboembolic events (3.5%). Transfusion rates were reported as 9.4% and 5.8% at M3 and M6, respectively. No EAB-related deaths were reported. Conclusions: EAB was effective and well-tolerated in the management of CIA. Clinical trial information: NCT01626547.
Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients
Authors: D. Ouzan, G. Penaranda, G. Lefolgoc, M. Antoni, P. Delasalle, T. Fontanges, P. Cerdan, P. Toulemonde, S. Bresson-Hadni, S. Beorchia, N. Boyer, B. Hanslik, H. Joly, J. Liautard, S. Baesjou, C. Bonny, P. Halfon, C. Renou, M. Bourliere
Journal: Journal of Hepatology (2017)
Switch or add-on peginterferon for chronic hepatitis B patients already on nucleos(t)ide analogue therapy (SWAP study): provisional analysis – add-on therapy superior
Authors: S.G. Lim, W.L. Yang, J. Ngu, J. Tan, T. Ahmed, Y.Y. Dan, K. Lim, Y.M. Lee, G.H. Lee, P.S. Tan, W.W. Phyo, J. Koo, C. Lee, A. Lee, E. Chan
Journal: Journal of Hepatology (2017)
Legal Complexities of Global Vaccine Compensation Systems—Reply
Authors: Sam F. Halabi, Saad B. Omer
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection
Authors: N. Reau, P.Y. Kwo, S. Rhee, R.S. Brown, K. Agarwal, P. Angus, E. Gane, J.-H. Kao, P.S. Mantry, K.R. Reddy, T.T. Tran, Y.B. Hu, A. Gulati, T.I. Ng, E.O. Dumas, N. Shulman, R. Trinh, X. Forns
Journal: Journal of Hepatology (2017)
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
Authors: A. Bamias, E. Gibbs, C. Khoon Lee, L. Davies, M. Dimopoulos, F. Zagouri, A.-S. Veillard, J. Kosse, A. Santaballa, M.R. Mirza, G. Tabaro, I. Vergote, H. Bloemendal, M. Lykka, A. Floquet, V. Gebski, E. Pujade-Lauraine
Journal: Annals of Oncology (2017)
Non-alcoholic fatty liver disease – demographic features, risk factors and treatment practices across the Asia Pacific region – the GO ASIA initiative
Authors: W.K. Chan, S. Treeprasertsuk, K. Imajo, A. Nakajima, Y. Seki, K. Kasama, S. Kakizaki, J.G. Fan, M.J. Song, S.K. Yoon, Y.Y. Dan, L. Lesmana, K.Y. Ho, K.L. Goh, V.W.S. Wong
Journal: Journal of Hepatology (2017)
Utilization of sofosbuvir/velpatasvir in genotype 2–6 HCV: real-world experience from the TRIO network
Authors: M. Curry, B. Bacon, D. Dieterich, S. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, N. Afdhal
Journal: Journal of Hepatology (2017)
Impact of Structural Cerebral Damage in Adults With Tetralogy of Fallot
Authors: Maayke A. Sluman, Edo Richard, Berto J. Bouma, Jan Willem van Dalen, Lennard L. van Wanrooij, Maarten Groenink, Matthan W. A. Caan, Aart J. Nederveen, Henk-Jan M. M. Mutsaerts, Charles B. L. M. Majoie, Ben A. Schmand, Barbara J. M. Mulder
Journal: Circulation (2017)
Interferon-free direct-acting antiviral therapy decreases the rate of hepatocellular carcinoma recurrence in patients with chronic hepatitis C and advanced fibrosis
Authors: V. Virlogeux, P. Pradat, K. Hartig-Lavie, F. Bailly, M. Maynard, G. Ouziel, D. Poinsot, F. Lebosse, M. Ecochard, S. Radenne, S. Benmakhlouf, J. Koffi, P. Lack, C. Scholtes, A.-C. Uhres, C. Ducerf, J.-Y. Mabrut, A. Rode, M. Levrero, C. Combet, P. Merle, F. Zoulim
Journal: Journal of Hepatology (2017)
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status
Authors: Angelo Agathanggelou, Edward Smith, Nicholas J. Davies, Marwan Kwok, Anastasia Zlatanou, Ceri E. Oldreive, Jingwen Mao, David Da Costa, Sina Yadollahi, Tracey Perry, Pamela Kearns, Anna Skowronska, Elliot Yates, Helen Parry, Peter Hillmen, Celine Reverdy, Remi Delansorne, Shankara Paneesha, Guy Pratt, Paul Moss, A. Malcolm R. Taylor, Grant S. Stewart, Tatjana Stankovic
Journal: Blood (2017)
Prospective study of autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct acting antivirals
Authors: D.A. Fernández, M.A. Suñer, M.J.F. Iglesias, C.L. Nuñez, I.S. Matamala, X.Q. Molés, X.A. Mante
Journal: Journal of Hepatology (2017)
Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy
Authors: Upasana Tayal, Simon Newsome, Rachel Buchan, Nicola Whiffin, Roddy Walsh, Paul J. Barton, James S. Ware, Stuart A. Cook, Sanjay K. Prasad
Journal: Journal of the American College of Cardiology (2017)

Dilated cardiomyopathy (DCM) has a population prevalence of ∼1 in 500 and is associated with prognostically adverse arrhythmias at initial disease presentation in up to one-third of patients [(1)][1]. While increasing age, male sex, and impaired ventricular function are established arrhythmic risk
Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools
Authors: F.M. Lamoury, B. Hajarizadeh, A. Soker, D. Martinez, C. Quek, P. Cunningham, B. Catlett, G.A. Cloherty, P. Marks, J. Amin, J. Grebely, G.J. Dore, T.L. Applegate
Journal: Journal of Hepatology (2017)
Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome
Authors: Viola Neudecker, Moritz Haneklaus, Owen Jensen, Ludmila Khailova, Joanne C. Masterson, Hazel Tye, Kathryn Biette, Paul Jedlicka, Kelley S. Brodsky, Mark E. Gerich, Matthias Mack, Avril A.B. Robertson, Matthew A. Cooper, Glenn T. Furuta, Charles A. Dinarello, Luke A. O’Neill, Holger K. Eltzschig, Seth L. Masters, Eóin N. McNamee
Journal: The Journal of Experimental Medicine (2017)

MicroRNA (miRNA)-mediated RNA interference regulates many immune processes, but how miRNA circuits orchestrate aberrant intestinal inflammation during inflammatory bowel disease (IBD) is poorly defined. Here, we report that miR-223 limits intestinal inflammation by constraining the nlrp3 inflammasome. miR-223 was increased in intestinal biopsies from patients with active IBD and in preclinical models of intestinal inflammation. miR-223-/y mice presented with exacerbated myeloid-driven experimental colitis with heightened clinical, histopathological, and cytokine readouts. Mechanistically, enhanced NLRP3 inflammasome expression with elevated IL-1β was a predominant feature during the initiation of colitis with miR-223 deficiency. Depletion of CCR2+ inflammatory monocytes and pharmacologic blockade of IL-1β or NLRP3 abrogated this phenotype. Generation of a novel mouse line, with deletion of the miR-223 binding site in the NLRP3 3' untranslated region, phenocopied the characteristics of miR-223-/y mice. Finally, nanoparticle-mediated overexpression of miR-223 attenuated experimental colitis, NLRP3 levels, and IL-1β release. Collectively, our data reveal a previously unappreciated role for miR-223 in regulating the innate immune response during intestinal inflammation.
A Magnetically Actuated Microscaffold Containing Mesenchymal Stem Cells for Articular Cartilage Repair
Authors: Gwangjun Go, Jiwon Han, Jin Zhen, Shaohui Zheng, Ami Yoo, Mi‐Jeong Jeon, Jong‐Oh Park, Sukho Park
Journal: Advanced Healthcare Materials (2017)

This study proposes a magnetically actuated microscaffold with the capability of targeted mesenchymal stem cell (MSC) delivery for articular cartilage regeneration. The microscaffold, as a 3D porous microbead, is divided into body and surface portions according to its materials and fabrication methods. The microscaffold body, which consists of poly(lactic‐co‐glycolic acid) (PLGA), is formed through water‐in‐oil‐in‐water emulsion templating, and its surface is coated with amine functionalized magnetic nanoparticles (MNPs) via amino bond formation. The porous PLGA structure of the microscaffold can assist in cell adhesion and migration, and the MNPs on the microscaffold can make it possible to steer using an electromagnetic actuation system that provides external magnetic fields for the 3D locomotion of the microscaffold. As a fundamental test of the magnetic response of the microscaffold, it is characterized in terms of the magnetization curve, velocity, and 3D locomotion of a single microscaffold. In addition, its function with a cargo of MSCs for cartilage regeneration is demonstrated from the proliferation, viability, and chondrogenic differentiation of D1 mouse MSCs that are cultured on the microscaffold. For the feasibility tests for cartilage repair, 2D/3D targeting of multiple microscaffolds with the MSCs is performed to demonstrate targeted stem cell delivery using the microscaffolds and their swarm motion.